AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, ...

CEO Jim Clemmer said the company has spent the last several years reshaping its portfolio and operating model, moving away ...

AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.

The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence The ALPHA-PE Research Fund is designed to support independent, physician-led research ...

AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected adjusted loss, but its GAAP loss was much bigger. AngioDynamics lost money in ...

Trowbridge announced, "Based on our first quarter performance and our expectations for the balance of the year, we now expect net sales to be in the range of $308 million to $313 million, raised from ...

AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release. The company’s BioFlo peripherally inserted central catheters ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

AngioDynamics Inc (NASDAQ: ANGO) has reported a Q4 FY23 adjusted EPS of $0.02, in line with the consensus EPS higher than $0.01 a year ago. Q4 sales increased 4.7% Y/Y to $91.07 million, beating the ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...

Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...